questionsmedicales.fr
Acides aminés, peptides et protéines
Protéines
Protéines et peptides de signalisation intracellulaire
Protein-tyrosine kinases
Protein-tyrosine kinases : Questions médicales fréquentes
Termes MeSH sélectionnés :
Diagnostic
5
Kinases
Biopsie
Tests sanguins
Marqueurs tumoraux
Kinases
CA 19-9
Tests génétiques
Mutations
Kinases
Antécédents familiaux
Cancer
Kinases
Symptômes
5
Fatigue
Perte de poids
Kinases
Kinases
Voies de signalisation
Symptômes
Cancers
Masse palpable
Saignements
Fatigue
Maladies
Symptômes
Évolution des symptômes
Surveillance
Kinases
Prévention
5
Prévention
Alimentation saine
Exercice
Dépistage
Anomalies
Kinases
Vaccins
Prévention
Kinases
Tabagisme
Facteurs de risque
Kinases
Facteurs environnementaux
Substances chimiques
Kinases
Traitements
5
Inhibiteurs de kinases
Imatinib
Traitements
Traitements personnalisés
Mutations
Kinases
Effets secondaires
Fatigue
Nausées
Radiothérapie
Traitements ciblés
Kinases
Efficacité des traitements
Rémission
Kinases
Complications
5
Complications
Résistance aux traitements
Progression de la maladie
Complications
Gestion
Kinases
Pronostic
Complications
Rémission
Type de cancer
Complications
Kinases
Traitements supplémentaires
Complications
Kinases
Facteurs de risque
5
Facteurs de risque
Antécédents familiaux
Tabagisme
Mode de vie
Risque
Kinases
Infections
Virus d'Epstein-Barr
Risque
Facteurs génétiques
Mutations
Kinases
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Protein-tyrosine kinases : Questions médicales les plus fréquentes",
"headline": "Protein-tyrosine kinases : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Protein-tyrosine kinases : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-05-05",
"dateModified": "2025-04-30",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Protein-tyrosine kinases"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Protéines et peptides de signalisation intracellulaire",
"url": "https://questionsmedicales.fr/mesh/D047908",
"about": {
"@type": "MedicalCondition",
"name": "Protéines et peptides de signalisation intracellulaire",
"code": {
"@type": "MedicalCode",
"code": "D047908",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Agammaglobulinaemia tyrosine kinase",
"alternateName": "Agammaglobulinaemia Tyrosine Kinase",
"url": "https://questionsmedicales.fr/mesh/D000077329",
"about": {
"@type": "MedicalCondition",
"name": "Agammaglobulinaemia tyrosine kinase",
"code": {
"@type": "MedicalCode",
"code": "D000077329",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.568.025"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Focal adhesion protein-tyrosine kinases",
"alternateName": "Focal Adhesion Protein-Tyrosine Kinases",
"url": "https://questionsmedicales.fr/mesh/D051416",
"about": {
"@type": "MedicalCondition",
"name": "Focal adhesion protein-tyrosine kinases",
"code": {
"@type": "MedicalCode",
"code": "D051416",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.568.049"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Janus kinases",
"alternateName": "Janus Kinases",
"url": "https://questionsmedicales.fr/mesh/D053612",
"about": {
"@type": "MedicalCondition",
"name": "Janus kinases",
"code": {
"@type": "MedicalCode",
"code": "D053612",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.568.124"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Janus kinase 1",
"alternateName": "Janus Kinase 1",
"url": "https://questionsmedicales.fr/mesh/D053613",
"about": {
"@type": "MedicalCondition",
"name": "Janus kinase 1",
"code": {
"@type": "MedicalCode",
"code": "D053613",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.568.124.100"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Janus kinase 3",
"alternateName": "Janus Kinase 3",
"url": "https://questionsmedicales.fr/mesh/D053616",
"about": {
"@type": "MedicalCondition",
"name": "Janus kinase 3",
"code": {
"@type": "MedicalCode",
"code": "D053616",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.568.124.300"
}
}
},
{
"@type": "MedicalWebPage",
"name": "TYK2 Kinase",
"alternateName": "TYK2 Kinase",
"url": "https://questionsmedicales.fr/mesh/D053634",
"about": {
"@type": "MedicalCondition",
"name": "TYK2 Kinase",
"code": {
"@type": "MedicalCode",
"code": "D053634",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.568.124.650"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Mitogen-Activated Protein Kinase Kinases",
"alternateName": "Mitogen-Activated Protein Kinase Kinases",
"url": "https://questionsmedicales.fr/mesh/D020929",
"about": {
"@type": "MedicalCondition",
"name": "Mitogen-Activated Protein Kinase Kinases",
"code": {
"@type": "MedicalCode",
"code": "D020929",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.568.200"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "MAP Kinase Kinase 1",
"alternateName": "MAP Kinase Kinase 1",
"url": "https://questionsmedicales.fr/mesh/D048369",
"about": {
"@type": "MedicalCondition",
"name": "MAP Kinase Kinase 1",
"code": {
"@type": "MedicalCode",
"code": "D048369",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.568.200.100"
}
}
},
{
"@type": "MedicalWebPage",
"name": "MAP Kinase Kinase 2",
"alternateName": "MAP Kinase Kinase 2",
"url": "https://questionsmedicales.fr/mesh/D048370",
"about": {
"@type": "MedicalCondition",
"name": "MAP Kinase Kinase 2",
"code": {
"@type": "MedicalCode",
"code": "D048370",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.568.200.200"
}
}
},
{
"@type": "MedicalWebPage",
"name": "MAP Kinase Kinase 3",
"alternateName": "MAP Kinase Kinase 3",
"url": "https://questionsmedicales.fr/mesh/D048371",
"about": {
"@type": "MedicalCondition",
"name": "MAP Kinase Kinase 3",
"code": {
"@type": "MedicalCode",
"code": "D048371",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.568.200.300"
}
}
},
{
"@type": "MedicalWebPage",
"name": "MAP Kinase Kinase 4",
"alternateName": "MAP Kinase Kinase 4",
"url": "https://questionsmedicales.fr/mesh/D048670",
"about": {
"@type": "MedicalCondition",
"name": "MAP Kinase Kinase 4",
"code": {
"@type": "MedicalCode",
"code": "D048670",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.568.200.400"
}
}
},
{
"@type": "MedicalWebPage",
"name": "MAP Kinase Kinase 5",
"alternateName": "MAP Kinase Kinase 5",
"url": "https://questionsmedicales.fr/mesh/D048671",
"about": {
"@type": "MedicalCondition",
"name": "MAP Kinase Kinase 5",
"code": {
"@type": "MedicalCode",
"code": "D048671",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.568.200.500"
}
}
},
{
"@type": "MedicalWebPage",
"name": "MAP Kinase Kinase 6",
"alternateName": "MAP Kinase Kinase 6",
"url": "https://questionsmedicales.fr/mesh/D048669",
"about": {
"@type": "MedicalCondition",
"name": "MAP Kinase Kinase 6",
"code": {
"@type": "MedicalCode",
"code": "D048669",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.568.200.600"
}
}
},
{
"@type": "MedicalWebPage",
"name": "MAP Kinase Kinase 7",
"alternateName": "MAP Kinase Kinase 7",
"url": "https://questionsmedicales.fr/mesh/D048688",
"about": {
"@type": "MedicalCondition",
"name": "MAP Kinase Kinase 7",
"code": {
"@type": "MedicalCode",
"code": "D048688",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.568.200.700"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Syk kinase",
"alternateName": "Syk Kinase",
"url": "https://questionsmedicales.fr/mesh/D000072377",
"about": {
"@type": "MedicalCondition",
"name": "Syk kinase",
"code": {
"@type": "MedicalCode",
"code": "D000072377",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.568.650"
}
}
},
{
"@type": "MedicalWebPage",
"name": "src-Family kinases",
"alternateName": "src-Family Kinases",
"url": "https://questionsmedicales.fr/mesh/D019061",
"about": {
"@type": "MedicalCondition",
"name": "src-Family kinases",
"code": {
"@type": "MedicalCode",
"code": "D019061",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.568.800"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "CSK tyrosine-protein kinase",
"alternateName": "CSK Tyrosine-Protein Kinase",
"url": "https://questionsmedicales.fr/mesh/D000081247",
"about": {
"@type": "MedicalCondition",
"name": "CSK tyrosine-protein kinase",
"code": {
"@type": "MedicalCode",
"code": "D000081247",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.568.800.158"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "ZAP-70 Protein-tyrosine kinase",
"alternateName": "ZAP-70 Protein-Tyrosine Kinase",
"url": "https://questionsmedicales.fr/mesh/D051746",
"about": {
"@type": "MedicalCondition",
"name": "ZAP-70 Protein-tyrosine kinase",
"code": {
"@type": "MedicalCode",
"code": "D051746",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.568.900"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Protein-tyrosine kinases",
"alternateName": "Protein-Tyrosine Kinases",
"code": {
"@type": "MedicalCode",
"code": "D011505",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Angela L Tyner",
"url": "https://questionsmedicales.fr/author/Angela%20L%20Tyner",
"affiliation": {
"@type": "Organization",
"name": "Department of Biochemistry and Molecular Genetics, University of Illinois at Chicago, Chicago, Illinois, USA; University of Illinois Cancer Center, University of Illinois at Chicago, Chicago, Illinois, USA. Electronic address: atyner@uic.edu."
}
},
{
"@type": "Person",
"name": "Eiji Kinoshita",
"url": "https://questionsmedicales.fr/author/Eiji%20Kinoshita",
"affiliation": {
"@type": "Organization",
"name": "Department of Functional Molecular Science, Institute of Biomedical & Health Sciences, Hiroshima University, Hiroshima 734-8553, Japan."
}
},
{
"@type": "Person",
"name": "Emiko Kinoshita-Kikuta",
"url": "https://questionsmedicales.fr/author/Emiko%20Kinoshita-Kikuta",
"affiliation": {
"@type": "Organization",
"name": "Department of Functional Molecular Science, Institute of Biomedical & Health Sciences, Hiroshima University, Hiroshima 734-8553, Japan."
}
},
{
"@type": "Person",
"name": "Tohru Koike",
"url": "https://questionsmedicales.fr/author/Tohru%20Koike",
"affiliation": {
"@type": "Organization",
"name": "Department of Functional Molecular Science, Institute of Biomedical & Health Sciences, Hiroshima University, Hiroshima 734-8553, Japan."
}
},
{
"@type": "Person",
"name": "Gongqin Sun",
"url": "https://questionsmedicales.fr/author/Gongqin%20Sun",
"affiliation": {
"@type": "Organization",
"name": "Department of Cell and Molecular Biology, University of Rhode Island, Kingston, RI, United States."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "The relevance of EGFR, ErbB receptors and neuregulins in human adipocytes and adipose tissue in obesity.",
"datePublished": "2022-11-09",
"url": "https://questionsmedicales.fr/article/36411648",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.biopha.2022.113972"
}
},
{
"@type": "ScholarlyArticle",
"name": "Non-equilibrium modalities of inhibition: Characterizing irreversible inhibition for the ErbB receptor family members.",
"datePublished": "2023-09-01",
"url": "https://questionsmedicales.fr/article/37858541",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/bs.mie.2023.08.004"
}
},
{
"@type": "ScholarlyArticle",
"name": "Regulation of ErbB Receptors by the Ca",
"datePublished": "2023-02-22",
"url": "https://questionsmedicales.fr/article/36979639",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/biomedicines11030661"
}
},
{
"@type": "ScholarlyArticle",
"name": "iRhom2 regulates ERBB signalling to promote KRAS-driven tumour growth of lung cancer cells.",
"datePublished": "2022-09-08",
"url": "https://questionsmedicales.fr/article/35971826",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1242/jcs.259949"
}
},
{
"@type": "ScholarlyArticle",
"name": "Simultaneously targeting ErbB family kinases and PI3K in HPV-positive head and neck squamous cell carcinoma.",
"datePublished": "2022-06-03",
"url": "https://questionsmedicales.fr/article/35667295",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.oraloncology.2022.105939"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Acides aminés, peptides et protéines",
"item": "https://questionsmedicales.fr/mesh/D000602"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines",
"item": "https://questionsmedicales.fr/mesh/D011506"
},
{
"@type": "ListItem",
"position": 4,
"name": "Protéines et peptides de signalisation intracellulaire",
"item": "https://questionsmedicales.fr/mesh/D047908"
},
{
"@type": "ListItem",
"position": 5,
"name": "Protein-tyrosine kinases",
"item": "https://questionsmedicales.fr/mesh/D011505"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Protein-tyrosine kinases - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Protein-tyrosine kinases",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-02",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Protein-tyrosine kinases",
"description": "Comment diagnostiquer une dysrégulation des kinases à tyrosine ?\nQuels marqueurs sont utilisés pour le diagnostic ?\nLes tests génétiques sont-ils utiles ?\nQuels examens d'imagerie sont recommandés ?\nLes antécédents familiaux influencent-ils le diagnostic ?",
"url": "https://questionsmedicales.fr/mesh/D011505?mesh_terms=ErbB+Receptors#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Protein-tyrosine kinases",
"description": "Quels symptômes sont liés à une suractivité des kinases ?\nLes symptômes varient-ils selon le type de kinase ?\nY a-t-il des symptômes spécifiques aux cancers ?\nLes symptômes peuvent-ils être confondus avec d'autres maladies ?\nComment les symptômes évoluent-ils dans le temps ?",
"url": "https://questionsmedicales.fr/mesh/D011505?mesh_terms=ErbB+Receptors#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Protein-tyrosine kinases",
"description": "Peut-on prévenir les dysfonctionnements des kinases ?\nLes dépistages réguliers sont-ils recommandés ?\nY a-t-il des vaccins préventifs ?\nLe tabagisme influence-t-il le risque ?\nLes facteurs environnementaux jouent-ils un rôle ?",
"url": "https://questionsmedicales.fr/mesh/D011505?mesh_terms=ErbB+Receptors#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Protein-tyrosine kinases",
"description": "Quels traitements ciblent les kinases à tyrosine ?\nLes traitements sont-ils personnalisés ?\nQuels effets secondaires des traitements sont courants ?\nLa radiothérapie est-elle utilisée ?\nLes traitements sont-ils efficaces à long terme ?",
"url": "https://questionsmedicales.fr/mesh/D011505?mesh_terms=ErbB+Receptors#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Protein-tyrosine kinases",
"description": "Quelles complications peuvent survenir avec les kinases ?\nLes complications sont-elles réversibles ?\nComment les complications affectent-elles le pronostic ?\nLes complications varient-elles selon le type de cancer ?\nLes complications nécessitent-elles des traitements supplémentaires ?",
"url": "https://questionsmedicales.fr/mesh/D011505?mesh_terms=ErbB+Receptors#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Protein-tyrosine kinases",
"description": "Quels sont les principaux facteurs de risque ?\nL'âge influence-t-il le risque de dysfonctionnement des kinases ?\nLe mode de vie joue-t-il un rôle ?\nLes infections peuvent-elles être un facteur de risque ?\nY a-t-il des facteurs génétiques impliqués ?",
"url": "https://questionsmedicales.fr/mesh/D011505?mesh_terms=ErbB+Receptors#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une dysrégulation des kinases à tyrosine ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests sanguins et des biopsies peuvent révéler des anomalies dans l'activité des kinases."
}
},
{
"@type": "Question",
"name": "Quels marqueurs sont utilisés pour le diagnostic ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les marqueurs tumoraux comme le CA 19-9 peuvent indiquer une activité kinase anormale."
}
},
{
"@type": "Question",
"name": "Les tests génétiques sont-ils utiles ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent identifier des mutations dans les gènes codant pour les kinases à tyrosine."
}
},
{
"@type": "Question",
"name": "Quels examens d'imagerie sont recommandés ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'IRM et le scanner peuvent aider à visualiser les tumeurs associées aux kinases."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux influencent-ils le diagnostic ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents de cancers peuvent augmenter le risque de dysrégulation des kinases."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont liés à une suractivité des kinases ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Fatigue, perte de poids, et douleurs osseuses peuvent indiquer une suractivité des kinases."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon le type de kinase ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes dépendent du type de kinase et de la voie de signalisation affectée."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes spécifiques aux cancers ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des symptômes comme des masses palpables ou des saignements peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les symptômes peuvent-ils être confondus avec d'autres maladies ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des symptômes comme la fatigue peuvent être communs à plusieurs maladies."
}
},
{
"@type": "Question",
"name": "Comment les symptômes évoluent-ils dans le temps ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils peuvent s'aggraver progressivement, nécessitant une surveillance régulière."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les dysfonctionnements des kinases ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation saine et l'exercice régulier peuvent réduire le risque de cancers."
}
},
{
"@type": "Question",
"name": "Les dépistages réguliers sont-ils recommandés ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des dépistages peuvent aider à détecter précocement des anomalies liées aux kinases."
}
},
{
"@type": "Question",
"name": "Y a-t-il des vaccins préventifs ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, il n'existe pas de vaccins spécifiques pour prévenir les dysfonctionnements des kinases."
}
},
{
"@type": "Question",
"name": "Le tabagisme influence-t-il le risque ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme est un facteur de risque connu pour plusieurs cancers liés aux kinases."
}
},
{
"@type": "Question",
"name": "Les facteurs environnementaux jouent-ils un rôle ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exposition à des substances chimiques peut augmenter le risque de dysfonctionnement des kinases."
}
},
{
"@type": "Question",
"name": "Quels traitements ciblent les kinases à tyrosine ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les inhibiteurs de kinases, comme l'imatinib, sont utilisés pour traiter certains cancers."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils personnalisés ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les traitements peuvent être adaptés en fonction des mutations spécifiques des kinases."
}
},
{
"@type": "Question",
"name": "Quels effets secondaires des traitements sont courants ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Fatigue, nausées et éruptions cutanées sont des effets secondaires fréquents."
}
},
{
"@type": "Question",
"name": "La radiothérapie est-elle utilisée ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la radiothérapie peut être utilisée en complément des traitements ciblés."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils efficaces à long terme ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'efficacité varie, mais certains patients peuvent bénéficier d'une rémission prolongée."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec les kinases ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications comme la résistance aux traitements et la progression de la maladie peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être gérées, mais d'autres peuvent être permanentes."
}
},
{
"@type": "Question",
"name": "Comment les complications affectent-elles le pronostic ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications peuvent aggraver le pronostic et réduire les chances de rémission."
}
},
{
"@type": "Question",
"name": "Les complications varient-elles selon le type de cancer ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les complications peuvent différer selon le type de cancer et la kinase impliquée."
}
},
{
"@type": "Question",
"name": "Les complications nécessitent-elles des traitements supplémentaires ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des traitements supplémentaires peuvent être nécessaires pour gérer les complications."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antécédents familiaux, le tabagisme et l'exposition à des produits chimiques sont des facteurs de risque."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque de dysfonctionnement des kinases ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque augmente généralement avec l'âge, surtout pour certains cancers."
}
},
{
"@type": "Question",
"name": "Le mode de vie joue-t-il un rôle ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie sédentaire et une mauvaise alimentation augmentent le risque."
}
},
{
"@type": "Question",
"name": "Les infections peuvent-elles être un facteur de risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines infections virales, comme le virus d'Epstein-Barr, peuvent augmenter le risque."
}
},
{
"@type": "Question",
"name": "Y a-t-il des facteurs génétiques impliqués ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des mutations génétiques héréditaires peuvent prédisposer à des dysfonctionnements des kinases."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 30/04/2025
Contenu vérifié selon les dernières recommandations médicales
3 publications dans cette catégorie
Affiliations :
Department of Biochemistry and Molecular Genetics, University of Illinois at Chicago, Chicago, Illinois, USA; University of Illinois Cancer Center, University of Illinois at Chicago, Chicago, Illinois, USA. Electronic address: atyner@uic.edu.
Publications dans "Protein-tyrosine kinases" :
3 publications dans cette catégorie
Affiliations :
Department of Functional Molecular Science, Institute of Biomedical & Health Sciences, Hiroshima University, Hiroshima 734-8553, Japan.
Publications dans "Protein-tyrosine kinases" :
3 publications dans cette catégorie
Affiliations :
Department of Functional Molecular Science, Institute of Biomedical & Health Sciences, Hiroshima University, Hiroshima 734-8553, Japan.
Publications dans "Protein-tyrosine kinases" :
3 publications dans cette catégorie
Affiliations :
Department of Functional Molecular Science, Institute of Biomedical & Health Sciences, Hiroshima University, Hiroshima 734-8553, Japan.
Publications dans "Protein-tyrosine kinases" :
3 publications dans cette catégorie
Affiliations :
Department of Cell and Molecular Biology, University of Rhode Island, Kingston, RI, United States.
Publications dans "Protein-tyrosine kinases" :
2 publications dans cette catégorie
Affiliations :
Department of Biochemistry and Molecular Genetics, University of Illinois at Chicago, Chicago, Illinois, USA.
Publications dans "Protein-tyrosine kinases" :
2 publications dans cette catégorie
Affiliations :
University of Massachusetts Chan Medical School, Worcester, United States. Electronic address: swati.jaiswal@umassmed.edu.
Publications dans "Protein-tyrosine kinases" :
2 publications dans cette catégorie
Affiliations :
Center for Cancer Training, NCI, and Digestive Diseases Branch, NIDDK, NIH, Bethesda, MD 20892, USA.
Publications dans "Protein-tyrosine kinases" :
2 publications dans cette catégorie
Affiliations :
Center for Cancer Training, NCI, and Digestive Diseases Branch, NIDDK, NIH, Bethesda, MD 20892, USA.
Publications dans "Protein-tyrosine kinases" :
2 publications dans cette catégorie
Affiliations :
Department of Psychiatry, Weill Cornell Medicine. New York, NY 10065, USA.
Publications dans "Protein-tyrosine kinases" :
2 publications dans cette catégorie
Affiliations :
Department of Psychiatry, Weill Cornell Medicine. New York, NY 10065, USA; Department of Biochemistry, Weill Cornell Medicine, New York, NY 10065, USA.
Publications dans "Protein-tyrosine kinases" :
2 publications dans cette catégorie
Affiliations :
Department of Psychiatry, Weill Cornell Medicine. New York, NY 10065, USA.
Publications dans "Protein-tyrosine kinases" :
2 publications dans cette catégorie
Affiliations :
Department of Biochemistry, Weill Cornell Medicine, New York, NY 10065, USA.
Publications dans "Protein-tyrosine kinases" :
2 publications dans cette catégorie
Affiliations :
Department of Psychiatry, Weill Cornell Medicine. New York, NY 10065, USA.
Publications dans "Protein-tyrosine kinases" :
2 publications dans cette catégorie
Affiliations :
Department of Psychiatry, Weill Cornell Medicine. New York, NY 10065, USA.
Publications dans "Protein-tyrosine kinases" :
2 publications dans cette catégorie
Affiliations :
Department of Psychiatry, Weill Cornell Medicine. New York, NY 10065, USA.
Publications dans "Protein-tyrosine kinases" :
2 publications dans cette catégorie
Affiliations :
Department of Life Sciences, Yeongnam University, Gyeongsan, Gyeongbuk 38451, South Korea.
Publications dans "Protein-tyrosine kinases" :
2 publications dans cette catégorie
Affiliations :
Department of Life Sciences, Yeongnam University, Gyeongsan, Gyeongbuk 38451, South Korea.
Publications dans "Protein-tyrosine kinases" :
2 publications dans cette catégorie
Affiliations :
Department of Biochemistry, Boston University School of Medicine, Boston, MA 02118, USA.
Publications dans "Protein-tyrosine kinases" :
2 publications dans cette catégorie
Affiliations :
Department of Psychiatry, Weill Cornell Medicine. New York, NY 10065, USA; Department of Biochemistry, Weill Cornell Medicine, New York, NY 10065, USA. Electronic address: jtl2003@med.cornell.edu.
Publications dans "Protein-tyrosine kinases" :
To investigate the potential role of EGFR, ErbBs receptors and neuregulins in human adipose tissue physiology in obesity....
Gene expression analysis in human subcutaneous (SAT) and visceral (VAT) adipose tissue in three independent cohorts [two cross-sectional (N = 150, N = 87) and one longitudinal (n = 25)], and in vitro ...
While both SAT and VAT ERBB2 and ERBB4 mRNA increased in obesity, SAT EGFR mRNA was negatively correlated with insulin resistance, but did not change in obesity. Of note, both SAT and VAT EGFR mRNA we...
This study demonstrates the association between adipose tissue ERBB2 and obesity, confirms the relevance of EGFR on human adipogenesis, and suggests a possible adipogenic role of NRG2....
Most drug target interactions for clinically approved small-molecules are non-equilibrium slow-onset, tight-binding or irreversible in nature, with pronounced element of time-dependence of inhibition....
Overexpression and mutations of the epidermal growth factor receptor (EGFR/ErbB1/HER1) and other tyrosine kinase receptors of the ErbB family (ErbB2/HER2, ErbB3/HER3 and ErbB4/HER4) play an essential ...
Dysregulation of the ERBB/EGFR signalling pathway causes multiple types of cancer. Accordingly, ADAM17, the primary shedding enzyme that releases and activates ERBB ligands, is tightly regulated. It h...
To identify the most effective PI3K and EGFR inhibitors in HPV-positive head and neck squamous cell carcinoma (HNSCC) and investigate the efficacy of a combination of an ErbB family kinase inhibitor a...
HPV-positive HNSCC cell lines were treated with the FDA approved ErbB kinase inhibitor, Afatinib or FDA-approved PI3K inhibitor, Copanlisib, alone or in combination, and phosphorylation and total prot...
Copanlisib more effectively inhibited cell proliferation in comparison to other PI3K inhibitors tested. HPV-positive HNSCC cells differentially responded to cisplatin, Afatinib, or Copanlisib. The com...
Afatinib and Copanlisib more effectively suppress cell proliferation and survival of HPV-positive HNSCC in comparison to either treatment alone....
This phase I/expansion study assessed the safety, pharmacokinetics and preliminary antitumor activity of afatinib in paediatric patients with cancer....
The dose-finding part enroled patients (2-<18 years) with recurrent/refractory tumours. Patients received 18 or 23 mg/m...
Of 564 patients pre-screened, 536 patients had biomarker data and 63 (12%) fulfilled ≥2 EGFR/HER2 criteria required for inclusion in the expansion part. A total of 56 patients were treated (17 in the ...
Targetable EGFR/HER2 drivers are rare in paediatric cancers. Treatment with afatinib led to a durable response (>3 years) in one patient with a glioneuronal tumour with CLIP2::EGFR fusion....
The ErbB RTKs (EGFR, HER2, HER3, and HER4) have been well-studied in cancer. EGFR, HER2, and HER3 stimulate cancer proliferation, principally by activating the phosphatidylinositol-3-kinase and extrac...
In general, human meningiomas grow slowly and have a favourable prognosis; however, some are prone to recur despite their benign histology. Therefore, knowledge of their tumour biology is essential to...
Targeting the HER2 oncogene represents one of the greatest advances in the treatment of breast cancer. HER2 is one member of the ERBB-receptor family, which includes EGFR (HER1), HER3 and HER4. In the...
Hepatocellular carcinoma (HCC) poses a significant global health challenge due to its poor prognosis and limited therapeutic modalities. Anoikis and ErbB signaling pathways are pivotal in cancer cell ...
This study evaluates the prognostic significance of anoikis and ErbB signaling pathways in HCC by utilizing data from The Cancer Genome Atlas (TCGA), the International Cancer Genome Consortium (ICGC),...
The single sample Gene Set Enrichment Analysis revealed a strong correlation between upregulated ErbB signaling in high anoikis-expressing tumors and poor clinical outcomes. The development of the Ano...
AERS provides a novel tool for clinical prognosis and paves the way for immune-targeted therapeutic approaches, underscoring the potential of integrated molecular profiling in enhancing treatment stra...